Jeffrey Tate

Jeffrey Tate, listed as senior executive, appears in our data through filings on Cyclo Therapeutics, Inc. shares, published by SEC (Form 4). We count 20 filings; the first trade dates from 1 August 2014 and the latest from 20 October 2023.

No open-market sale appears; the market trades are 8 purchases worth €43k. The totals exclude 2 filings filed without an amount. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Outside the open market, there are 11 share grants. So far in 2023, the count stands at 1 purchase and no sales.

Half of the purchases are above €4,417 and half below. 3 out of 6 purchases came within 30 days of a purchase by at least one other insider of the same company. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase.

The record was last updated on 23 October 2023 with a share grant (€20k) in Cyclo Therapeutics, Inc. The last purchase on record was published on 24 April 2023, which is 1,295 days ago. The median gap between a trade and its publication by SEC (Form 4) is 3 days. The legal deadline for a Form 4 is two business days after the transaction. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.